Breast cancer survivors have a meaningfully elevated risk of developing non-Hodgkin lymphoma compared to the general population. A large nationwide cohort study found the risk roughly 64% higher after adjusting for lifestyle and health factors, with the increase especially pronounced in younger women diagnosed before age 50. The connection involves multiple overlapping causes, from the treatments used against breast cancer itself to shared genetic vulnerabilities, and the signs can be easy to mistake for a breast cancer recurrence or a benign problem.
How Large Is the Risk Increase?
A Korean nationwide cohort study tracking breast cancer survivors over time found that developing breast cancer was associated with a fully adjusted hazard ratio of 1.64 for non-Hodgkin lymphoma, meaning survivors were about 64% more likely to develop it than matched women who never had breast cancer. That figure held after accounting for body mass index, alcohol intake, physical activity, smoking, income, and other health conditions.1Blood Cancer Journal. Risk of non-Hodgkin lymphoma in breast cancer survivors: a nationwide cohort study
Age at breast cancer diagnosis made a striking difference. Women under 50 when diagnosed faced nearly triple the lymphoma risk compared to the general population, while women 50 and older had a more modest 36% increase. The reasons for this age gap are not fully understood, but younger women tend to receive more aggressive treatment regimens, including higher cumulative doses of chemotherapy and more cycles of radiation, which may contribute to the wider gap.
It helps to put these numbers in perspective. Non-Hodgkin lymphoma is not a common cancer to begin with. Even a 64% relative increase on top of a low baseline rate means that the vast majority of breast cancer survivors will never develop lymphoma. The elevated risk matters more as a reason for awareness than as a reason for alarm.
Why Breast Cancer Treatment Can Set the Stage for Lymphoma
Several treatment-related mechanisms can nudge the immune system toward lymphoma development. Radiation therapy, chemotherapy, and newer targeted drugs each carry distinct risks.
Radiation therapy after breast cancer surgery increases the overall rate of secondary cancers. A study of nearly 375,000 breast cancer patients found that those who received radiation had a secondary malignancy rate modestly but significantly higher than those treated without it, and about 3.4% of all secondary cancers in the cohort were directly attributable to radiation exposure.2Elsevier / The Breast. Risk of secondary malignancies after radiation therapy for breast cancer: Comprehensive results Lymphoma is among those secondary cancers, though solid tumors in adjacent tissue (lung, esophagus, the opposite breast) account for a larger share. The risk from radiation builds slowly, and case reports have documented lymphoma appearing in a previously irradiated breast field as late as 40 years after the original treatment.3Cureus. Diffuse Large B-cell Lymphoma of the Breast Presenting 40 Years After Breast-Conserving Therapy: A Case Report
Chemotherapy, particularly alkylating agents and topoisomerase inhibitors used in breast cancer regimens, can damage the DNA of blood-forming cells. Case series have documented diffuse large B-cell lymphoma, angioimmunoblastic lymphoma, and mantle cell lymphoma arising as secondary blood cancers after systemic chemotherapy for breast cancer.4PubMed. Secondary hematological malignancies after breast cancer chemotherapy The damage typically involves stem cells in the bone marrow acquiring mutations over years, eventually producing a cancerous clone of white blood cells.
A newer concern involves PARP inhibitors, a class of targeted therapy increasingly used for breast cancers linked to BRCA mutations. These drugs work by blocking a DNA-repair pathway in cancer cells, but they can also stress the repair machinery of healthy blood cells. Reports of secondary blood cancers, including lymphoid malignancies, have surfaced in patients treated with PARP inhibitors, raising questions about long-term monitoring for survivors on these drugs.5PubMed Central. PARP Inhibitors and Haematological Malignancies-Friend or Foe?
Shared Genetics Between Breast Cancer and Lymphoma
Not all lymphoma in breast cancer survivors is caused by treatment. Some of the overlap traces back to inherited genetic mutations that raise the risk of both diseases independently. BRCA1 and BRCA2 are best known for their role in breast and ovarian cancer, but research has shown that pathogenic variants in both genes are also associated with lymphoma risk.6PubMed Central. Association between germline pathogenic variants in cancer-predisposing genes and lymphoma risk This means a woman who carries a BRCA mutation and develops breast cancer was already at somewhat elevated risk for lymphoma before her breast cancer treatment even began.
The practical implication is that genetic counseling matters. If you carry a known cancer-predisposition mutation, your oncologist may factor that into surveillance planning, watching for signs of blood cancers alongside the more familiar screening for breast, ovarian, and pancreatic cancer. This shared genetic ground also partly explains why the elevated lymphoma risk in the cohort data persists even after adjusting for treatment variables.
Which Types of Lymphoma Appear Most Often
The nationwide cohort study broke down the risk by lymphoma subtype and found that the increase was not spread evenly. Anaplastic large cell lymphoma, or ALCL, showed the sharpest spike, with a more than sevenfold increase in risk among breast cancer survivors. Follicular lymphoma risk was roughly three and a half times higher, and mature T/NK-cell lymphoma risk was nearly triple that of women without breast cancer.7Blood Cancer Journal. Risk of non-Hodgkin lymphoma in breast cancer survivors: a nationwide cohort study – Section: Results
Diffuse large B-cell lymphoma, the most common aggressive subtype of non-Hodgkin lymphoma in general, also appears among breast cancer survivors, particularly after chemotherapy exposure.4PubMed. Secondary hematological malignancies after breast cancer chemotherapy The range of subtypes matters because treatment and prognosis differ substantially. Follicular lymphoma tends to grow slowly and may be watched for years before treatment is needed, while diffuse large B-cell lymphoma typically requires prompt chemotherapy. ALCL occupies a special category, particularly in the context of breast implants.
Breast Implant-Associated Lymphoma
Breast implant-associated anaplastic large cell lymphoma, known as BIA-ALCL, deserves separate attention because its cause and presentation differ from other post-treatment lymphomas. This is a T-cell non-Hodgkin lymphoma that develops in the tissue capsule surrounding a breast implant. It is not breast cancer, and it is not caused by radiation or chemotherapy. Instead, the primary risk factor is the use of textured-surface implants, which are thought to trigger chronic local inflammation and sustained immune stimulation that can eventually push T cells toward cancerous growth.8JAMA Surgery. Breast Implant–Associated Anaplastic Large Cell Lymphoma: A Systematic Review
The disease typically appears long after implant placement. The average time from implant insertion to BIA-ALCL diagnosis ranges from about 7 to 13 years.9PubMed Central. Breast Implant-Associated Lymphoma In roughly 80% of cases, the first sign is a late-developing seroma, meaning unexplained fluid buildup around the implant that causes swelling on one side. The remaining cases present as a firm mass near the implant, sometimes accompanied by fluid as well.8JAMA Surgery. Breast Implant–Associated Anaplastic Large Cell Lymphoma: A Systematic Review
BIA-ALCL is relevant to breast cancer survivors specifically because many women receive implants as part of post-mastectomy reconstruction. The lymphoma cells are typically CD30-positive and ALK-negative, which distinguishes them from other forms of ALCL.10PubMed. Breast Implant-Associated Anaplastic Large Cell Lymphoma: Where Hematology and Plastic Surgery Meet The condition is rare in absolute terms, but any woman with textured implants who notices new swelling, pain, or a lump near the implant years after surgery should have it evaluated promptly. Early-stage BIA-ALCL confined to the capsule has an excellent prognosis when treated with complete implant and capsule removal. Advanced cases may require chemotherapy.
Signs That Should Prompt Evaluation
Lymphoma in a breast cancer survivor can show up in two broad ways: as a mass or swelling in the breast itself, or as enlarged lymph nodes elsewhere in the body. The tricky part is that both can initially mimic breast cancer recurrence, leading to delays in correct diagnosis.
When lymphoma develops within breast tissue (called secondary breast lymphoma), it tends to produce multiple smaller lesions rather than the single dominant mass more typical of breast carcinoma. The individual lesions are often smaller than a primary breast cancer mass, and the clinical presentation can be more subtle, sometimes found incidentally on imaging rather than felt as a lump.11PubMed Central. Primary and secondary breast lymphoma: prevalence, clinical signs and radiological features – Section: Results Secondary breast lymphoma is actually the most common type of metastasis to the breast from another cancer, accounting for about 17% of all metastatic disease found in breast tissue.12PubMed. Primary and Secondary Breast Lymphoma: Clinical, Pathologic, and Multimodality Imaging Review
Lymphoma can also announce itself through enlarged lymph nodes outside the breast’s normal drainage area. A case report of a 35-year-old woman who had simultaneous breast cancer and non-Hodgkin lymphoma illustrates the principle: the enlarged lymph node was in her neck, a location that would be unusual for breast cancer spread. The clinical lesson from that case is that swollen lymph nodes in unexpected locations should be investigated as potentially separate malignancies rather than automatically assumed to be metastatic breast cancer.13PubMed Central. Synchronous breast cancer and non-Hodgkin lymphoma: A case report – Section: Presentation of case
Other symptoms to watch for include unexplained fevers, drenching night sweats, and unintentional weight loss. These “B symptoms” are classic features of lymphoma and are uncommon in breast cancer recurrence. Persistent fatigue that worsens over weeks without a clear cause can also be an early signal, though it overlaps with many other conditions.
How Lymphoma in the Breast Is Distinguished from Recurrent Breast Cancer
When a new mass appears in the breast of someone with a cancer history, the default assumption is usually recurrence. But the two diseases look and behave differently on imaging and under the microscope, and getting the distinction right changes everything about treatment.
On imaging, primary breast lymphoma tends to present as a single, relatively large mass, while secondary breast lymphoma (lymphoma that started elsewhere and spread to the breast) more often shows multiple smaller lesions.11PubMed Central. Primary and secondary breast lymphoma: prevalence, clinical signs and radiological features – Section: Results An older patient presenting with multiple breast masses and a more subtle clinical picture is more likely to have secondary lymphoma than a primary breast tumor.12PubMed. Primary and Secondary Breast Lymphoma: Clinical, Pathologic, and Multimodality Imaging Review
PET/CT imaging with radioactive glucose (FDG) can help, since lymphoma and breast carcinoma take up glucose differently. Research into the radiomic texture features of PET/CT scans suggests that combining standard glucose-uptake measurements with computational texture analysis may reliably distinguish breast lymphoma from breast carcinoma, and even differentiate between lymphoma subtypes.14PubMed Central. Ability of (18)F-FDG PET/CT Radiomic Features to Distinguish Breast Carcinoma from Breast Lymphoma In practice, though, a tissue biopsy with specialized staining remains the gold standard. Pathologists look for markers that identify lymphocytes rather than epithelial cells, which is how breast carcinoma is confirmed. Getting the biopsy right matters enormously: lymphoma is treated with chemotherapy regimens like R-CHOP, not with the surgery-first approaches common in breast cancer. Operating on a lymphoma that was mistaken for a breast cancer recurrence provides no benefit and delays effective treatment.
Treatment When Both Cancers Overlap
Treating lymphoma in someone who has already been through breast cancer therapy raises practical concerns about cumulative toxicity. Many chemotherapy drugs used for lymphoma overlap with or compound the side effects of prior breast cancer treatment. Anthracyclines like doxorubicin, for instance, are central to the R-CHOP regimen for diffuse large B-cell lymphoma, but they also carry cumulative heart toxicity. A woman who already received an anthracycline for breast cancer has a lower ceiling for how much more her heart can tolerate.
A pilot study looking at breast cancer patients who had previously received radiation for Hodgkin lymphoma (essentially the reverse scenario, but informative about treatment tolerance across cancers) found that most patients handled subsequent chemotherapy reasonably well. Taxane-based regimens were tolerated by about 75% of patients, and anthracycline-based regimens were tolerated by all 15 patients studied.15PubMed. A pilot study evaluating chemotherapy tolerability for breast cancer patients who have received prior treatment and chest radiation for Hodgkin Lymphoma – Section: RESULTS While these numbers come from a small study and the direction of overlap was reversed, they suggest that sequential treatment for two different cancers is feasible with careful monitoring.
For BIA-ALCL, the treatment approach is different. When the lymphoma is confined to the implant capsule, complete surgical removal of the implant and capsule is often curative on its own. More advanced cases, where the lymphoma has spread beyond the capsule into surrounding tissue or lymph nodes, may require chemotherapy and occasionally radiation. The staging at diagnosis is the strongest predictor of outcome.
The Cognitive Toll of Compounded Treatment
One underappreciated consequence of being treated for two cancers is the cumulative effect on brain function. The phenomenon broadly called “chemo brain” is well documented in both breast cancer and lymphoma survivors individually, but facing two rounds of systemic treatment compounds the issue.
A study of long-term survivors of breast cancer and lymphoma found that those treated with systemic chemotherapy scored significantly lower on neuropsychological tests than survivors treated with local therapy alone, particularly in verbal memory and psychomotor speed. About 39% of chemotherapy-treated survivors scored in the lowest quartile of cognitive performance, compared to 14% of those who received only local treatment. The chemotherapy group also reported more day-to-day problems with working memory.16PubMed Central / Journal of Clinical Oncology. Neuropsychologic impact of standard-dose systemic chemotherapy in long-term survivors of breast cancer and lymphoma
For someone facing a second cancer that also requires chemotherapy, these cognitive effects can stack. Discussing this openly with your oncology team before treatment starts allows for baseline cognitive testing and planning. Some cancer centers now offer cognitive rehabilitation programs, and simple strategies like keeping written to-do lists and building more recovery time into daily routines can make a meaningful difference during and after treatment.
When Lymphoma Reaches the Skin
A less common but clinically important scenario involves lymphoma spreading to the skin, which can be confused with inflammatory breast cancer or radiation-related skin changes in a breast cancer survivor. A study of secondary cutaneous lymphomas found that T-cell and NK-cell types accounted for roughly 56% of cases, with B-cell types making up about 35%. Patients whose skin involvement appeared within six months of their primary lymphoma diagnosis had significantly worse survival than those whose skin disease developed later. Disseminated skin lesions also carried a worse outlook than localized ones.17British Journal of Dermatology. Secondary cutaneous lymphoma: comparative clinical features and survival outcome analysis of 106 cases according to lymphoma cell lineage
For breast cancer survivors, the takeaway is that new skin changes in or near the treated breast that do not respond to standard wound care or look different from expected radiation effects should be biopsied rather than observed. Skin-directed lymphoma can sometimes be managed with local radiation or topical therapies when caught early, but the window for those less aggressive approaches narrows once lesions become widespread.
The Reverse Direction and Why It Matters
The relationship between breast cancer and lymphoma runs both ways. People treated for Hodgkin lymphoma, particularly those who received chest radiation at a young age, face a well-documented elevated risk of subsequent breast cancer. That elevated breast cancer risk emerges about five years after lymphoma treatment and persists for decades, with the gap between irradiated and non-irradiated patients widening sharply after 15 years.18The Oncologist. Risk, Characteristics, and Prognosis of Breast Cancer after Hodgkin’s Lymphoma – Section: Results
This bidirectional relationship reinforces the idea that these two cancers share vulnerabilities at the level of DNA repair, immune surveillance, and treatment-induced damage. For people navigating survivorship of either cancer, the clinical lesson is the same: ongoing screening and attention to new symptoms in the years and decades after treatment remain important. A woman cured of Hodgkin lymphoma in her twenties may need breast MRI screening starting at a younger age than the general population, and a breast cancer survivor should mention any persistent lymph node swelling, unexplained fevers, or night sweats to her care team rather than assuming they are benign.